AI brief of an SEC Form 8-K · Adagio Medical Holdings, Inc. (ADGM)

Adagio Medical cuts 25 of 43 jobs and starts strategic review of alternatives

Negative Impact 4 of 5 restructuring Written later

Adagio Medical said its board has begun a formal process to explore strategic alternatives, including a possible acquisition, merger or other transaction, and is reducing its workforce by 25 of 43 full-time employees effective September 23, 2026. The company also said it will lower the conversion price on its 13% Senior Secured Convertible Notes from September 23, 2026 through October 31, 2026, which could result in more shares being issued on conversion, and that there is no assurance any transaction will occur.

Key points

  • Workforce reduction of 25 of 43 full-time employees, effective September 23, 2026
  • Estimated cash expenditures of approximately $1.3 million, mainly one-time severance, benefits and related costs; additional charges, including possible impairments, cannot yet be estimated
  • Conversion price on the 13% Senior Secured Convertible Notes to be lowered for conversions from September 23, 2026 through October 31, 2026, subject to extension
  • Preliminary unaudited cash, equivalents and marketable securities of approximately $7.7 million as of June 30, 2026; no timetable set for the strategic review

The filing

CompanyAdagio Medical Holdings, Inc. (ADGM)
Form8-K, current report
Filed with the SECSep 23, 2026, 8:01 AM ET
Accession number0001104659-26-109821

Items reported: 2.05 Exit / Restructuring Costs8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.